News
Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback